Arnon Nagler

发表

Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects

M. Labopin, A. Nagler, M. Mohty, 2015, Bone Marrow Transplantation.

CAR-T cells: the narrow path between hope and bankruptcy?

S. Montoto, N. Kröger, A. Nagler, 2017, Bone Marrow Transplantation.

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants

A. Gennery, N. Kröger, A. Nagler, 2015, Bone Marrow Transplantation.

Halofuginone inhibits NF‐κB and p38 MAPK in activated T cells

A. Nagler, M. Leiba, L. Cahalon, 2006 .

Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced

A. Nagler, A. Chetrit, R. Yerushalmi, 2013, Leukemia.

Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome

N. Kröger, M. Labopin, I. Yakoub-Agha, 2014, Bone Marrow Transplantation.

Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP

A. Nagler, M. Mohty, P. Dreger, 2014, Bone Marrow Transplantation.

Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report

S. Montoto, A. Gennery, N. Kröger, 2017, Bone Marrow Transplantation.

The presence of a single PML-RARA isoform lacking exon 5 in FISH-negative APL samples

A. Nagler, O. Ashur-Fabian, L. Trakhtenbrot, 2008, Leukemia.

Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation

A. Nagler, N. Amariglio, A. Shimoni, 2008, Leukemia.

Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fluda

A. Nagler, R. Yerushalmi, A. Shimoni, 2007, Leukemia.

Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation

F. Baron, M. Labopin, D. Blaise, 2012, Leukemia.

Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen

A. Nagler, D. Engelhard, S. Slavin, 2001, Bone Marrow Transplantation.

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

A. Nagler, R. Yerushalmi, A. Shimoni, 2006, Leukemia.

Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model

A. Nagler, V. Doviner, Y. Ilan, 2003, Bone Marrow Transplantation.

Assessment of the coagulation profile in hemato-oncological patients receiving ATG-based conditioning treatment for allogeneic stem cell transplantation

A. Nagler, B. Sela, A. Shimoni, 2004, Bone Marrow Transplantation.

Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study.

O. Koren, R. Yerushalmi, A. Eshel, 2024, Bone marrow transplantation.

Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?

M. Labopin, A. Nagler, M. Mohty, 2016, Leukemia.

G-CSF-primed BM for allogeneic SCT: revisited

A. Nagler, A. Shimoni, I. Pessach, 2015, Bone Marrow Transplantation.

Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet™) combined morphological and cytogenetical analysis

A. Nagler, L. Trakhtenbrot, N. Amariglio, 2002, Leukemia.

Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia

A. Nagler, M. Mohty, A. Bacigalupo, 2017, Bone Marrow Transplantation.

Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT)

A. Gennery, N. Kröger, A. Nagler, 2017, Bone Marrow Transplantation.

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT

N. Kröger, J. Finke, A. Nagler, 2016, Annals of Hematology.

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up

A. Nagler, R. Yerushalmi, A. Shimoni, 2010, Leukemia.

CT in the clinical and prognostic evaluation of acute graft-vs-host disease of the gastrointestinal tract.

R. Yerushalmi, A. Shimoni, L. Guranda, 2012, The British journal of radiology.

Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity

A. Nagler, R. Yerushalmi, A. Shimoni, 2012, Bone Marrow Transplantation.

Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations

A. Nagler, A. Shimoni, A. Shimoni, 2001, Leukemia.

Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike

A. Nagler, A. Shimoni, A. Shimoni, 2012, Bone Marrow Transplantation.

The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT

G. Mufti, C. Craddock, M. Labopin, 2013, Bone Marrow Transplantation.